Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision ...

After a decade of development, a Kansas City-based pharmaceutical company is on the brink of submitting its ADHD medication ...

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla.

The Trump administration is now accepting applications for a pilot program to demo rebates for 340B drugs that drugmakers ...

In this symposium, an expert panel will discuss how the latest organoid models help researchers discover and develop new ...

Shareholders sued over what they saw as a breach of fiduciary duties by the board of directors regarding the drug Anktiva, ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

The FDA has cleared investigational new drug applications for ZW251 and RV‑01, advancing novel treatments for solid tumors in ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.